IRVINE, Calif.--(BUSINESS WIRE)--
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), (the "Company"), announced
today that its first quarter 2017 financial results will be released
after the market closes on Tuesday, May 2, 2017. Following the release,
the Company will host a live conference call and webcast at 5:00 p.m.
Eastern Time to discuss the Company's financial results and provide a
general business update.
The live webcast and a replay may be accessed by visiting the Company's
website at http://investors.aeriepharma.com.
Please connect to the Company's website at least 15 minutes prior to the
live webcast to ensure adequate time for any software download that may
be needed to access the webcast. Alternatively, please call (888)
734-0328 (U.S.) or (678) 894-3054 (international) to listen to the live
conference call. The conference ID number for the live call is 7178517.
Please dial in approximately 10 minutes prior to the call. Telephone
replay will be available approximately two hours after the call. To
access the replay, please call (855) 859-2056 (U.S.) or (404) 537-3406
(international). The conference ID number for the replay is 7178517. The
telephone replay will be available until May 9, 2017.
About Aerie Pharmaceuticals, Inc.
Aerie is a clinical-stage pharmaceutical company focused on the
discovery, development and commercialization of first-in-class therapies
for the treatment of patients with glaucoma and other diseases of the
eye. Aerie's two lead product candidates are once-daily intraocular
pressure-lowering therapies with novel mechanisms of action to treat
patients with glaucoma or ocular hypertension. The NDA for RhopressaTM
(netarsudil ophthalmic solution) 0.02% was submitted to the FDA in
February 2017. Aerie's second product candidate, RoclatanTM
(netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, which is a
fixed dose combination of RhopressaTM and widely prescribed
PGA latanoprost, currently has two Phase 3 registration trials underway,
named Mercury 1 and Mercury 2. If these trials are successful, a RoclatanTM
NDA submission is expected to take place in late 2017 or early 2018.
Aerie is also focused on the development of additional product
candidates and technologies in ophthalmology.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170425005119/en/
Richard Rubino, 908-947-3540
McClellan, Inc., on behalf of Aerie Pharmaceuticals
Source: Aerie Pharmaceuticals, Inc.
News Provided by Acquire Media